Approved and development of passive and active immunizations against respiratory syncytial virus in childhood and pregnancy

In a recent study published in Journal of Pediatricsresearchers investigated active and passive childhood vaccination against respiratory syncytial virus (RSV). Study: Current strategies and perspectives for active and passive immunization against respiratory syncytial virus in childhood. Image credit: ART-ur/Shutterstock Background Despite the global importance of RSV infections in children, only one monoclonal antibody, Palivizumab, has … Read more

Research findings may bolster the effectiveness of immune checkpoint therapy

Immune checkpoint inhibitors like Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumor cells. Their introduction ten years ago represented a major advancement in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement. In an article published online today in The Journal of Clinical Research (JCI), … Read more

Progress and challenges in the development of respiratory syncytial virus mRNA vaccines

A recent review published in Cytokine and Growth Factor Reviews discussed the structure and life cycle of the respiratory syncytial virus (RSV), current research on the treatment and prevention of RSV infections, and the advancements in RSV messenger ribonucleic acid (mRNA) vaccine technology following the wave of vaccine research during the coronavirus disease 2019 (Covid19 … Read more

Monoclonal antibody shows efficacy in preventing malaria infection in African adults

A dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical study has found. The antibody was up to 88.2% effective in preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody … Read more